IL17A and type 1 diabetes mellitus: Increasing evidence has shown that therapeutic agents targeting the IL-17 molecule or directly inhibiting IL-17-producing cells regulate autoimmune diabetes, suggesting that IL-17 is involved in the pathogenesis of T1D [49].